Kera Capital Partners, Inc. Phathom Pharmaceuticals, Inc. Transaction History
Kera Capital Partners, Inc.
- $483 Million
- Q2 2025
A detailed history of Kera Capital Partners, Inc. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Kera Capital Partners, Inc. holds 30,059 shares of PHAT stock, worth $263,617. This represents 0.06% of its overall portfolio holdings.
Number of Shares
30,059
Previous 29,849
0.7%
Holding current value
$263,617
Previous $187 Million
99.85%
% of portfolio
0.06%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding PHAT
# of Institutions
151Shares Held
66.6MCall Options Held
94KPut Options Held
55.5K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$88.7 Million3.99% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$65.5 Million20.28% of portfolio
-
Jennison Associates LLC7.04MShares$61.8 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$32 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$30.7 Million27.15% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $344M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...